Author:
Germing Ulrich,Fenaux Pierre
Publisher
Springer International Publishing
Reference95 articles.
1. Silverman LR, Holland JF, Weinberg RS, Alter BD, Davis RB, Ellison RR, Demakos EP, Cornell CJ CRW Jr, Schiffer C. Effects of treatment with 5–azacytidine on the in vivo and in-vitro hematopoiesis patients with myelodysplastic syndromes. Leukemia. 1993;7(Suppl 1):21–9.
2. Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for selective benefit of sequential treatment with hypomethylating agents in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2017;17(4):211–4.
3. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang J, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–9.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–9.